NCT00382239 - A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

exenatide (LY2148568)

subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks

DRUG

exenatide (LY2148568)

subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks

DRUG

exenatide (LY2148568)

subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks

DRUG

Placebo

subcutaneous injection twice daily, 0.02 mL to 0.04 mL

Trial Locations (14)

Research Site, Fukuoka

Research Site, Fukushima

Research Site, Gunma

Research Site, Hiroshima

Research Site, Hyōgo

Research Site, Ibaraki

Research Site, Kanagawa

Research Site, Kumamoto

Research Site, Kyoto

Research Site, Nagano

Research Site, Okayama

Research Site, Osaka

Research Site, Ōita

Research Site, Tokyo